Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Fungal Infection Reports
Erschienen in: Current Fungal Infection Reports 1/2012

01.03.2012 | Current Management of Fungal Infections (L Ostrosky-Zeichner, Section Editor)

Medical Mycology for the Hospital Epidemiologist

verfasst von: Michelle A. Barron

Erschienen in: Current Fungal Infection Reports | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Healthcare-associated invasive fungal infections are increasing and are a cause of significant patient morbidity and mortality. Nosocomial infections due to Candida species, followed by Aspergillus species, are the most common causes of these infections in hospitalized patients. Hospital epidemiologists and infection control practitioners must recognize that similar to bacterial pathogens, fungal infections can be the cause of hospital outbreaks, and issues of resistance are increasing. Efforts to best identify patients at risk for developing fungal infections or those at risk of having a resistant organism are ongoing. Better diagnostics and tools to aid prevention are needed in addition to usual infection prevention and control standards.
Literatur
1.
Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003;3(11):685–702.PubMedCrossRef
2.
Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36(9):1103–10.PubMedCrossRef
3.
Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39(3):309–17.PubMedCrossRef
4.
• Sydnor ER and Perl TM. Hospital epidemiology and infection control in acute-care settings. Clin Microbiol Rev. 2011; 24(1):141–173. This is a comprehensive review of hospital epidemiology and infection control practices in the acute care setting as well as the changing roles of hospital epidemiologists and infection control practitioners.
5.
• Smith JA, Kauffman CA. Recognition and prevention of nosocomial invasive fungal infections in the intensive care unit. Crit Care Med. 2010; 38(8 Suppl):S380-S387. This article very nicely outlines the epidemiology and prevention strategies associated with nosocomial fungal infections.
6.
Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48(12):1695–703.PubMedCrossRef
7.
Luzzati R, Allegranzi B, Antozzi L, et al. Secular trends in nosocomial candidaemia in non-neutropenic patients in an Italian tertiary hospital. Clin Microbiol Infect. 2005;11(11):908–13.PubMedCrossRef
8.
Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20(1):133–63.PubMedCrossRef
9.
Ortega M, Marco F, Soriano A, et al. Candida species bloodstream infection: epidemiology and outcome in a single institution from 1991 to 2008. J Hosp Infect. 2011;77(2):157–61.PubMedCrossRef
10.
Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. 2008;112(11):2493–9.PubMedCrossRef
11.
Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008–2009. Antimicrob Agents Chemother. 2011;55(2):561–6.PubMedCrossRef
12.
Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis. 1996; 22 Suppl 2S89-S94.
13.
Diekema DJ, Messer SA, Hollis RJ, Wenzel RP, Pfaller MA. An outbreak of Candida parapsilosis prosthetic valve endocarditis. Diagn Microbiol Infect Dis. 1997;29(3):147–53.PubMedCrossRef
14.
Masala L, Luzzati R, Maccacaro L, et al. Nosocomial cluster of Candida guillermondii fungemia in surgical patients. Eur J Clin Microbiol Infect Dis. 2003;22(11):686–8.PubMedCrossRef
15.
Hautala T, Ikaheimo I, Husu H, et al. A cluster of Candida krusei infections in a haematological unit. BMC Infect Dis. 2007;7:97.
16.
Vazquez JA, Boikov D, Boikov SG, Dajani AS. Use of electrophoretic karyotyping in the evaluation of Candida infections in a neonatal intensive-care unit. Infect Control Hosp Epidemiol. 1997;18(1):32–7.PubMedCrossRef
17.
de Repentigny L, Reiss E. Current trends in immunodiagnosis of candidiasis and aspergillosis. Rev Infect Dis. 1984;6(3):301–12.PubMedCrossRef
18.
Peman J, Zaragoza R. Current diagnostic approaches to invasive candidiasis in critical care settings. Mycoses. 2010;53(5):424–33.PubMedCrossRef
19.
Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2005;43(12):5957–62.PubMedCrossRef
20.
Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327–60.PubMedCrossRef
21.
Mennink-Kersten MA, Warris A, Verweij PE. 1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med. 2006;354(26):2834–5.PubMedCrossRef
22.
Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004;39(2):199–205.PubMedCrossRef
23.
Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1–>3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005;41(5):654–9.PubMedCrossRef
24.
Senn L, Robinson JO, Schmidt S, et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis. 2008;46(6):878–85.PubMedCrossRef
25.
• Mohr JF, Sims C, Paetznick V, et al. Prospective survey of (1-->3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J Clin Microbiol. 2011; 49(1):58–61. This prospective study evaluated the use of BG in the setting of ICU patients at risk for the development of invasive candidiasis (IC). The authors were able to use this test as a diagnostic tool for predicting which patients would later develop IC.
26.
Burnie JP, Golbang N, Matthews RC. Semiquantitative polymerase chain reaction enzyme immunoassay for diagnosis of disseminated candidiasis. Eur J Clin Microbiol Infect Dis. 1997;16(5):346–50.PubMedCrossRef
27.
Chryssanthou E, Klingspor L, Tollemar J, et al. PCR and other non-culture methods for diagnosis of invasive Candida infections in allogeneic bone marrow and solid organ transplant recipients. Mycoses. 1999;42(4):239–47.PubMedCrossRef
28.
Einsele H, Hebart H, Roller G, et al. Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol. 1997;35(6):1353–60.PubMed
29.
Florent M, Katsahian S, Vekhoff A, et al. Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies. J Infect Dis. 2006;193(5):741–7.PubMedCrossRef
30.
Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1–>3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol. 2004;42(6):2733–41.PubMedCrossRef
31.
van Burik JA, Myerso D, Schreckhise RW, Bowden RA. Panfungal PCR assay for detection of fungal infection in human blood specimens. J Clin Microbiol. 1998;36(5):1169–75.PubMed
32.
Verweij PE, Meis JF. Microbiological diagnosis of invasive fungal infections in transplant recipients. Transpl Infect Dis. 2000;2(2):80–7.PubMedCrossRef
33.
Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol. 2011;49(2):665–70.PubMedCrossRef
34.
Cohen Y, Karoubi P, Adrie C, et al. Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients. Crit Care Med. 2010;38(3):826–30.PubMedCrossRef
35.
Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220(6):751–8.PubMedCrossRef
36.
Leon C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006;34(3):730–7.PubMedCrossRef
37.
Leon C, Ruiz-Santana S, Saavedra P, et al. Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med. 2009;37(5):1624–33.PubMedCrossRef
38.
Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis. 2007;26(4):271–6.PubMedCrossRef
39.
Ostrosky-Zeichner L, Pappas PG, Shoham S, et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses. 2011;54(1):46–51.PubMedCrossRef
40.
• van de Veerdonk FL, Netea MG, Joosten LA, van der Meer JW, Kullberg BJ. Novel strategies for the prevention and treatment of Candida infections: the potential of immunotherapy. FEMS Microbiol Rev. 2010; 34(6):1063–1075. This is a review of the current immunology of Candida infections and the potential for treatment and prevention strategies using vaccines and immunotherapy.
41.
Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503–35.PubMedCrossRef
42.
Schuster MG, Edwards Jr JE, Sobel JD, et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med. 2008;149(2):83–90.PubMed
43.
Sable CA, Donowitz GR. Infections in bone marrow transplant recipients. Clin Infect Dis. 1994;18(3):273–81.PubMedCrossRef
44.
Singh N, Pursell KJ. Combination therapeutic approaches for the management of invasive aspergillosis in organ transplant recipients. Mycoses. 2008;51(2):99–108.PubMedCrossRef
45.
Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol. 2005;43 Suppl 1:S49–58.PubMedCrossRef
46.
Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis. 2001;33(11):1824–33.PubMedCrossRef
47.
Kedzierska A, Kochan P, Pietrzyk A, Kedzierska J. Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1–>3)-beta-D-glucan antigens. Eur J Clin Microbiol Infect Dis. 2007;26(11):755–66.PubMedCrossRef
48.
Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001;97(6):1604–10.PubMedCrossRef
49.
Maertens J, Van Eldere J, Verhaegen J, et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis. 2002;186(9):1297–306.PubMedCrossRef
50.
Maertens J, Glasmacher A, Selleslag D, et al. Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study. Clin Infect Dis. 2005;41(1):e9–e14.PubMedCrossRef
51.
Wheat LJ, Hackett E, Durkin M, et al. Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol. 2007;14(5):638–40.PubMedCrossRef
52.
Viscoli C, Machetti M, Cappellano P, et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis. 2004;38(6):913–6.PubMedCrossRef
53.
Sulahian A, Touratier S, Ribaud P. False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med. 2003;349(24):2366–7.PubMedCrossRef
54.
Singh N, Obman A, Husain S, et al. Reactivity of platelia Aspergillus galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum. Antimicrob Agents Chemother. 2004;48(6):1989–92.PubMedCrossRef
55.
Adam O, Auperin A, Wilquin F, et al. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis. 2004;38(6):917–20.PubMedCrossRef
56.
Miceli MH, Grazziutti ML, Woods G, et al. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis. 2008; 461412–1422.
57.
Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41(9):1242–50.PubMedCrossRef
58.
Clancy CJ, Jaber RA, Leather HL, et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol. 2007;45(6):1759–65.PubMedCrossRef
59.
Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008;177(1):27–34.PubMedCrossRef
60.
Musher B, Fredricks D, Leisenring W, et al. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol. 2004;42(12):5517–22.PubMedCrossRef
61.
Patterson TF. Risk stratification for invasive aspergillosis: early assessment of host susceptibility. Med Mycol. 2009;47 Suppl 1:S255–60.PubMedCrossRef
62.
Singh N. Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis. 2000;31(2):545–53.PubMedCrossRef
63.
Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev. 2005;18(1):44–69.PubMedCrossRef
64.
Baddley JW, Andes DR, Marr KA, et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis. 2010;50(12):1559–67.PubMedCrossRef
65.
66.
Dykewicz CA, Jaffe HW, Spira J, et al. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep. 2000;49(RR-10):1–128.
Metadaten
Titel
Medical Mycology for the Hospital Epidemiologist
verfasst von
Michelle A. Barron
Publikationsdatum
01.03.2012
Verlag
Current Science Inc.
Erschienen in
Current Fungal Infection Reports / Ausgabe 1/2012
Print ISSN: 1936-3761
Elektronische ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-011-0077-3

Weitere Artikel der Ausgabe 1/2012

Current Fungal Infection Reports 1/2012 Zur Ausgabe

Current Management of Fungal Infections (L Ostrosky-Zeichner, Section Editor)

Aspergillus in the Intensive Care Unit

Current Management of Fungal Infections (L Ostrosky-Zeichner, Section Editor)

Biomarkers for Diagnosis of Candidal Infections

Current Management of Fungal Infections (L Ostrosky-Zeichner, Section Editor)

IRIS and Fungal Infections: What Have We Learned?

Current Management of Fungal Infections (L Ostrosky-Zeichner, Section Editor)

Is There Still a Place for Conventional Amphotericin B in the Treatment of Neonatal Fungal Infections?

Current Management of Fungal Infections (L Ostrosky-Zeichner, Section Editor)

Antifungal Susceptibility Testing of Filamentous Fungi

Current Management of Fungal Infections (L Ostrosky-Zeichner, Section Editor)

Epidemiology of Invasive Fungal Infections in Latin America

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise